Testosterone replacement therapy: intent matters

Affiliations

Comment

Michael S Lauer. Lancet Diabetes Endocrinol. 2016 Jun.

. 2016 Jun;4(6):471-3.

doi: 10.1016/S2213-8587(16)30008-0. Epub 2016 May 7.

¹ Office of Extramural Research, National Institutes of Health, Bethesda, MD 20892, USA. Electronic address: Michael.Lauer@nih.gov.

No abstract available

Comment on

Survival and cardiovascular events in men treated with testosterone replacement therapy: an intention-to-treat observational cohort study.
Wallis CJ, Lo K, Lee Y, Krakowsky Y, Garbens A, Satkunasivam R, Herschorn S, Kodama RT, Cheung P, Narod SA, Nam RK. Wallis CJ, et al. Lancet Diabetes Endocrinol. 2016 Jun;4(6):498-506. doi: 10.1016/S2213-8587(16)00112-1. Epub 2016 May 7. Lancet Diabetes Endocrinol. 2016. PMID: 27165609